Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination
Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1372-1381
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Differences in incidence and fatality of COVID‐19 by SARS‐CoV‐2 Omicron variant versus Delta variant in relation to vaccine coverage: A world‐wide review
Chao Wang, Bei Liu, Sihui Zhang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 100
Expert review on global real-world vaccine effectiveness against SARS-CoV-2
Sunate Chuenkitmongkol, Rontgene Solante, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 9, pp. 1255-1268
Open Access | Times Cited: 38
PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals
Amitis Ramezani, Rahim Sorouri, Saiedeh Haji‐Maghsoudi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
Haoyue Cheng, Zhicheng Peng, Shuting Si, et al.
Vaccines (2022) Vol. 10, Iss. 5, pp. 798-798
Open Access | Times Cited: 31
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 29
Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
Nungruthai Suntronwong, Sitthichai Kanokudom, Chompoonut Auphimai, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 12, pp. 5713-5722
Open Access | Times Cited: 26
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
Chao Wang, Linyi Chen, Qing‐Bin Lu, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 920-920
Open Access | Times Cited: 24
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
Nungruthai Suntronwong, Ritthideach Yorsaeng, Jiratchaya Puenpa, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 391-391
Open Access | Times Cited: 23
The Coming of Age of Nucleic Acid Vaccines during COVID-19
Halie M. Rando, Ronan Lordan, Likhitha Kolla, et al.
mSystems (2023) Vol. 8, Iss. 2
Open Access | Times Cited: 13
Omicron variants breakthrough infection elicited higher specific memory immunity than third dose booster in healthy vaccinees
Pei Yu, Zijian Liu, Zhuoqi Zhu, et al.
Virologica Sinica (2023) Vol. 38, Iss. 2, pp. 233-243
Open Access | Times Cited: 12
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
Rituparna Das, Randall N. Hyer, Paul R. Burton, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 12
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
Xuejun Wang, Lin Yao, Hong‐Yun Zhang, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 19
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
Moe H. Kyaw, Júlia Spinardi, Ling Zhang, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 11
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
Sana Eybpoosh, Alireza Biglari, Rahim Sorouri, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 11, pp. e1011744-e1011744
Open Access | Times Cited: 11
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection
Nungruthai Suntronwong, Sitthichai Kanokudom, Chompoonut Auphimai, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 180-180
Open Access | Times Cited: 3
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine
Viravarn Luvira, Punnee Pitisuttithum
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 283-293
Open Access | Times Cited: 3
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
Mohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112192-112192
Closed Access | Times Cited: 3
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
Suvichada Assawakosri, Sitthichai Kanokudom, Jira Chansaenroj, et al.
International Journal of Infectious Diseases (2022) Vol. 122, pp. 793-801
Open Access | Times Cited: 17
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 64-72
Open Access | Times Cited: 15
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Sitthichai Kanokudom, Suvichada Assawakosri, Nungruthai Suntronwong, et al.
Vaccine (2022) Vol. 40, Iss. 39, pp. 5657-5663
Open Access | Times Cited: 14
Real-World Effectiveness of a Booster Dose of the COVID-19 Vaccines among Japanese University Students
Shunsuke Miyauchi, Toru Hiyama, Yukiko Nakano, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1283-1283
Open Access | Times Cited: 13
The importance of booster vaccination in the context of Omicron wave
Zichun Wei, Jiarui He, Conghui Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Omicron BA.1, BA.2 and COVID-19 Booster Vaccination
Suvichada Assawakosri, Sitthichai Kanokudom, Nungruthai Suntronwong, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 8, pp. 1480-1481
Open Access | Times Cited: 11
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 570-570
Open Access | Times Cited: 6
Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration
Germain Simon, Julien Favresse, Constant Gillot, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 61, Iss. 10, pp. 1875-1885
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top